Assenagon Asset Management S.A. Sells 3,222,008 Shares of Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 92.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 267,054 shares of the biopharmaceutical company’s stock after selling 3,222,008 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Gilead Sciences were worth $32,778,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Trivium Point Advisory LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. Binnacle Investments Inc increased its stake in shares of Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares during the last quarter. Hemington Wealth Management raised its holdings in shares of Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares in the last quarter. Ignite Planners LLC raised its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in shares of Gilead Sciences by 0.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after buying an additional 87 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a large, strategic move to deepen its cell‑therapy franchise and obtain rights to anito‑cel; analyst commentary highlights anito‑cel as a meaningful revenue opportunity (GlobalData forecasts ~$658m sales by 2032), reinforcing the company’s long‑term growth story. Gilead doubles down on cell therapy
• Positive Sentiment: Gilead is buying Ouro Medicines for up to ~$2.18B to add OM336 (gamgertamig), a BCMAxCD3 T‑cell engager for autoimmune disease — a move that expands its inflammation/immunology pipeline and led to analyst and press coverage framing the deal as a second major bolt‑on after Arcellx. Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal
• Positive Sentiment: Analyst/press takes (e.g., Barron’s, TipRanks) emphasize the strategic rationale — “immune reset” and broader immunology exposure — which likely bolstered investor confidence and buying interest following the deal announcements. Gilead to Buy Ouro Medicines for $2.2 Billion
• Neutral Sentiment: MaxCyte (a supplier/peer in cell therapy) reported a Q4 revenue miss — an industry data point investors may watch for supply or partner‑execution implications, but it does not directly change Gilead’s announced M&A strategy. MaxCyte Q4 Report
• Neutral Sentiment: Several short‑interest reports posted for March show large increases but contain erroneous/zeroed values (NaN/0), so there’s no clear short‑pressure signal to explain moves; treat the data as unreliable until exchanges update filings.
• Neutral Sentiment: Other sector news (Weave Bio advisory board, broad market mover roundups) is background noise and unlikely to be a primary driver of GILD’s intraday move. Weave Bio Advisory Board

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the insider directly owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 309,280 shares of company stock worth $44,068,850. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GILD shares. Barclays began coverage on Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price on the stock. Truist Financial increased their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Finally, Leerink Partners upped their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $138.26 on Thursday. The business has a 50 day moving average of $143.59 and a 200-day moving average of $128.39. The company has a market capitalization of $171.61 billion, a P/E ratio of 20.42, a P/E/G ratio of 1.81 and a beta of 0.37. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period last year, the company earned $1.90 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.